Ensartinib plus anlotinib for lorlatinib-resistant ALK lung cancer
Part of Cancer clinical trials.
This trial tests a combination of two targeted medicines, ensartinib and anlotinib, for people with ALK-positive non-small cell lung cancer that has stopped responding to the drug lorlatinib. It aims to see if the combination can shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced non-small cell lung cancer that is ALK-positive (a certain gene change).
- You have tried lorlatinib and it stopped working.
- You have taken no more than two other ALK-targeted medicines (and not ensartinib).
- You have taken no more than two courses of chemotherapy.
- You are 18 or older and your physical ability (ECOG score) is 0 to 2 (able to care for yourself).
- You do not have another active cancer, and if you have brain/spine lining spread, you must be able to have a contrast MRI.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This real-world study looks at how ensartinib works in people with advanced ALK-positive non-small cell lung cancer (NSCLC) whose disease has continued or worsened after ALK-targeted therapy. It may help doctors understand how well the treatment works and who benefits most in everyday care.
This trial tests whether taking the targeted therapy Ensartinib (which blocks ALK) along with standard chemotherapy before surgery can help shrink ALK-positive lung cancer and improve outcomes. It is for people who have not yet had treatment and whose cancer is at a stage that can be removed with surgery.
This study combines a daily targeted pill (lorlatinib) with a short course of radiation or surgery to treat ALK-positive lung cancer. The goal is to see if this two-step approach delays the cancer from growing.
This trial tests whether the drug ensartinib can help prevent cancer from returning after standard chemoradiation in people with stage III ALK-mutated non-small cell lung cancer that cannot be removed by surgery. Enrolling those who have completed chemoradiation within the past 6 weeks without their cancer getting worse.
This trial tests the targeted therapy drug ensartinib given after surgery to prevent lung cancer from coming back. It is only for people whose tumor has an ALK gene change and who are in early to moderately advanced stages after complete removal.
This trial tests combining chemotherapy with lorlatinib for people with ALK-positive lung cancer that has spread outside the brain while on lorlatinib. The goal is to see if adding chemo can help control the cancer when it starts growing again.
Hear when a new ALK-positive, Locally Advanced or Metastatic (TNM Stage IIIB-IV) Non-small Cell Lung Cancer That Has Developed Resistance to Prior Treatment With Lorlatinib trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.